Neurocrine Biosciences
NBIX
NBIX
721 hedge funds and large institutions have $14.1B invested in Neurocrine Biosciences in 2025 Q4 according to their latest regulatory filings, with 132 funds opening new positions, 278 increasing their positions, 220 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
3% more capital invested
Capital invested by funds: $13.6B → $14.1B (+$437M)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
42% less call options, than puts
Call options by funds: $41.3M | Put options by funds: $71.6M
Holders
721
Holding in Top 10
10
Calls
$41.3M
Puts
$71.6M
Top Buyers
| 1 | +$101M | |
| 2 | +$92.3M | |
| 3 | +$89.7M | |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$72.2M |
| 5 |
JP Morgan Chase
New York
|
+$68.1M |
Top Sellers
| 1 | -$144M | |
| 2 | -$103M | |
| 3 | -$89.5M | |
| 4 |
Millennium Management
New York
|
-$77.4M |
| 5 |
Jennison Associates
New York
|
-$73M |